Phase I study of the combination of everolimus (RAD001) with panitumumab in patients with refractory solid malignancies. Background: S-1 is an oral, fixed-dose combination product comprised of tegafur ...
Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States A single 1,500-mg, oral dose of lapatinib was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results